Thromboembolism and anticoagulant therapy during the COVID-19 pandemic: interim clinical guidance from the anticoagulation forum
Overview
Paper Summary
The guidance recommends pharmacologic VTE prophylaxis for all hospitalized COVID-19 patients, suggests increased doses for critically ill patients, and advises against routine extended prophylaxis post-discharge. It also recommends using anti-Xa assays to monitor unfractionated heparin and suggests against using D-dimer to guide therapy.
Explain Like I'm Five
Scientists found that people with COVID-19 in the hospital can get blood clots, so doctors give them special medicine to stop these tiny blockages from forming, especially if they are very sick.
Possible Conflicts of Interest
Some authors disclosed receiving grant funding or consulting fees from pharmaceutical companies.
Identified Limitations
Rating Explanation
This paper provides important interim guidance on a critical issue during the COVID-19 pandemic. Although based on expert opinion and limited data, it offers a structured and rational approach to anticoagulation in COVID-19 patients, addressing key questions and acknowledging limitations. The disclosed conflicts of interest are noted but don't appear to significantly detract from the value of the guidance.
Good to know
This is the Starter analysis. Paperzilla Pro fact-checks every citation, researches author backgrounds and funding sources, and uses advanced AI reasoning for more thorough insights.
Explore Pro →